SOLICITATION NOTICE
B -- Provide functional screening using Drosophila model systems
- Notice Date
- 8/4/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-211-DLM
- Archive Date
- 8/28/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Brown University, Department of Molecular Cell Biology and Biochemistry, SFH Life Science Building, Box G-L 164, 185 Meeting Street, Providence, Rhode Island 02912 to provide functional screening using Drosophila model systems for Undiagnosed Disease Program (UDP), NHGRI. Procurement: 1. First, a functional screen will be carried out using Drosophila model systems to establish and analyze the effect of expression of two different human mutant candidate genes of the human gene SLC13A5 identified in the UDP program as being associated with severe seizure disorders; and 2. Second, construct "humanized" versions of the normal and mutant SLC13A5 genes in Drosophila to study directly the effects of SLC13A5 mutants in the Drosophila model system, and to avoid problems that can occur with overexpression of human genes in Drosophila. Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to the NIH and often have numerous and/or complex medical problems. The UDP program makes use of a diverse set of diagnostic and research techniques both to attempt to find a diagnosis and to generate research projects to advance medical knowledge. The Brown University, Department of Molecular Biology, Cell Biology, and Biochemistry laboratory of Dr. Stephen Helfand focuses on molecular genetic mechanisms on Drosophila melanogaster and he has been performing functional analysis of human mutations in Drosophila for over 20 years. This collaboration will continue to support the UDP to provide functional analysis of suspected gene mutations to determine disease causation in UDP patients. The laboratory of Dr. Helfand at Brown University has expertise in molecular genetics and performing functional analysis of human mutations in Drosophila melanogaster with the numerous studies of genes associated with human aging and neurodegeneration. Additionally, supports the ongoing collaborative research expertise needed by the National Human Genome Research Institute (NHGRI), Undiagnosed Disease Program (UDP) in order to functionally analyze specific mutations for phenotypes to determine possible disease causality. Purpose and Objectives : The purpose of this acquisition is to provide functional screening for two different mutant candidate genes in SLC13A5 by screening 20 candidate lines in Drosophila for mutations seen in NIH Undiagnosed Diseases Program patients. Specifically, this laboratory supports the research needs of the UDP by collaborating on particular clinically identified new and rare neurological diseases. Period of Performance : 18-Months Upon Award Project Description : Contractor's Requirements : • The Contractor shall establish and analyze the expression of two human mutant candidates in SLC13A5 that have been associated with severe seizure disorders in UDP patients. • The Contractor shall ubiquitously overexpress the SLC13A5 normal human and mutant genes to functionally analyze the phenotypic effects on development and maturity with a heavy emphasis on the neurological phenotypes of these genes. • The Contractor shall overexpress the SLC13A5 normal human and mutant genes on specific sets of nervous system cells to functionally analyze the phenotypic effects on development and maturity with a heavy emphasis on the neurological phenotypes of these genes. • The Contractor shall construct "humanized" versions of the SLC13A5 normal and mutant genes in Drosophila to study the direct effects of the mutants in Drosophila to avoid the overexpression problems that may occur. • The Contractor shall provide unique services specific to genes suspected of causing neurological disease to meet the program goals of the UDP. • The Contractor's turn-around-time for UDP to receive data in 3 months and all results within 18 months of contract approval. • The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source. CLOSING STATEMENT: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-76 (July 25, 2014). This requirement is under the Simplified Acquisition Threshold of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received August 13, 2014, 8:00 A.M. Eastern Time and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-211-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency." Faxes will not be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-211-DLM/listing.html)
- Place of Performance
- Address: Contractor's Location, United States
- Record
- SN03448539-W 20140806/140804234707-94c77d1bef3a5fdac6472afe35734c4e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |